AbbVie ends work on cancer drug after failures By Rebecca Spalding Aug 29, 2019 10:29 AM - AbbVie Inc. said it would stop all research on its experimental cancer...
AbbVie Inc. said it would stop all research on its experimental cancer treatment Rova-T, a drug it bought in its $5.8 billion 2016 takeover of Stemcentrx Inc.
